It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

(RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake City-based company said it had a loss of 41 cents. The results did not meet Wall Street ...